Document is current
Any future updates will be listed below
-
Authors
Chen, Wei-Qiang
Lou, Li
Qiang, Xiao-Ling
Zhu, Cassie Shu
Li, Jian-Hua
Chen, Shu-Jin
Xiong, Brian
Yang, Huan
Wang, Ping
Tracey, Kevin J.
Wang, Hai-Chao https://orcid.org/0000-0002-0211-9000
-
Funding
Funding for this research was provided by:
NIGMS (R35GM145331)
NICCH (R01AT005076)
- License Information
-
More Information
Article History
Received: 3 October 2025
Accepted: 30 January 2026
First Online: 17 February 2026
Declarations
:
: The animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of the Feinstein Institutes for Medical Research (Protocol #2017–027 Term II, August 24, 2020; #2023–002, April 6, 2023; and #2024–0846, October 29, 2024).
: Not applicable.
: JHL, KJT, and HCW are coinventors on US Patent 11,124,558 (“Use of tetranectin and peptide agonists to treat inflammatory diseases”, issued September 21, 2021) and a provisional patent application (“Therapeutic use of a tetranectin-derived peptide P2-1 for rheumatoid arthritis”, filed September 15, 2025). CSZ and HCW are coinventors on a US Patent Application (“Use of procathepsin L-neutralizing monoclonal antibodies to treat sepsis, rheumatoid arthritis, and other inflammatory diseases”, filed April 18, 2024). All the other authors declare that they have no conflicts of interest.
